ovarian cancer
AZ and MSD’s Lynparza secures CHMP nod in first-line BRCA-mutated ovarian cancer
April 29, 2019Sales and Marketing AstraZeneca, CHMP, Cancer, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s Lynparza (olaparib) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use …
Pfizer and Merck discontinue Phase 3 avelumab ovarian cancer trial
March 20, 2019Research and Development Merck KGaA, Pfizer, javelin, oncology, ovarian cancer
Pfizer and Merck KGaA have chosen to discontinue the Phase 3 JAVELIN trial looking into avelumab in combination with chemotherapy …
GSK acquires oncology firm Tesaro for $5.1 billion
January 23, 2019Research and Development Cancer, GSK, Tesaro, oncology, ovarian cancer
British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion). Tesaro, a Massachusetts-based clinical stage …
AstraZeneca scores hat trick in ovarian cancer and anaemia clinical trials
December 20, 2018Research and Development AstraZeneca, anaemia, oncology, ovarian cancer, pharma
Anglo-Swedish multinational AstraZeneca has revealed that its ovarian cancer drug (Lynparza) and anaemia treatment (Roxadustat) have met their goals in …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
AstraZeneca’s Lynparza proves efficacy in first-line BRCA-mutated advanced ovarian cancer
June 27, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, Merck, ovarian cancer, pharma
AstraZeneca is celebrating alongside partner MSD with the reveal of new data on the use of Lynparza in the first-line …
European approval for tablet formulation of Lynparza in ovarian cancer
May 8, 2018Research and Development, Sales and Marketing AstraZeneca, Cancer, EMA, Europe, MSD, lynparza, ovarian cancer, pharma
AstraZeneca and MSD’s poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) has been approved for use in Europe, it has emerged, …
Ovarian cancer rates set to rise by 55%
May 1, 2018Manufacturing and Production, Medical Communications biotech, drugs, ovarian cancer, pharma, pharmaceutical
Ahead of World Ovarian Cancer Day on 8 May, new figures have been released suggesting that rates of this type …
J&J pays out $37m in damages over claims its talc contains asbestos
April 6, 2018Medical Communications, Sales and Marketing Cancer, J&J, JJ, Johnson & Johnson, mesothelioma, ovarian cancer, pharma, talc
Bad news for Johnson & Johnson as it emerges that the US pharma giant has been ordered to pay out …
Patient experience: Living with ovarian cancer
April 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Ingrid Copperman, feature, ovarian cancer, patient experience, pharma
Ingrid Copperman recounts the many ways she has dealt with her diagnosis, as well as how the power of social …
FDA authorises first direct-to-consumer test for BRCA mutations, with caveats
March 6, 2018Research and Development, Sales and Marketing 23andME, BRCA, Cancer, FDA, breast cancer, ovarian cancer, pharma
The FDA has given its authorisation to the first ever direct-to-consumer (DTC) test to identify three BRCA gene mutations which …
Ovarian cancer risk may be inherited from the father, research indicates
February 16, 2018Medical Communications, Research and Development Cancer, Roswell Park Comprehensive Cancer Centre, ovarian cancer
Researchers at the Roswell Park Comprehensive Cancer Centre in New York have published findings indicating that ovarian cancer risk may …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
UK underperforming in cancer care compared to Europe, according to ABPI report
July 18, 2017Research and Development ABPI, Cancer, Pancreatic cancer, biotech, heralthcare, lung cancer, ovarian cancer, pharma, pharmaceutical
According to a new report commissioned by the ABPI, the UK is continuing to fall behind in the diagnosis and …
Breakthrough treatment for ovarian cancer displays promising results
June 5, 2017Research and Development, Sales and Marketing Amgen, Cancer, ICR, ovarian cancer
A treatment that specifically targets ovarian cancer cells has shown that half of women who took the drug experienced shrinking …
Latest content
